3,206
Views
18
CrossRef citations to date
0
Altmetric
Original Articles

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

, , , , , ORCID Icon, , , , , , & show all
Pages 368-376 | Received 14 May 2020, Accepted 23 Sep 2020, Published online: 03 Nov 2020